Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) have earned an average recommendation of “Buy” from the twelve ratings firms that are covering the firm. Five analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $7.39.

Several research analysts have recently commented on the company. Roth Capital set a $7.00 price target on Celldex Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 2nd. Aegis assumed coverage on Celldex Therapeutics in a research report on Monday, November 7th. They issued a “buy” rating for the company. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research report on Thursday. Wedbush reissued a “neutral” rating and issued a $3.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 9th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research note on Monday, October 10th.

Celldex Therapeutics (NASDAQ:CLDX) opened at 4.32 on Thursday. The company’s market cap is $434.35 million. The stock has a 50 day moving average price of $3.66 and a 200 day moving average price of $4.04. Celldex Therapeutics has a 1-year low of $2.85 and a 1-year high of $18.62.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. The firm earned $2.20 million during the quarter, compared to analyst estimates of $1.09 million. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. The business’s revenue for the quarter was up 115.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.32) EPS. On average, equities research analysts anticipate that Celldex Therapeutics will post ($1.29) EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Veritable L.P. purchased a new stake in Celldex Therapeutics during the second quarter valued at $132,000. Virginia Retirement Systems ET AL purchased a new stake in Celldex Therapeutics during the third quarter valued at $150,000. Canada Pension Plan Investment Board increased its stake in Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 33,800 shares during the last quarter. Bank of Montreal Can purchased a new stake in Celldex Therapeutics during the second quarter valued at $188,000. Finally, BlackRock Advisors LLC increased its stake in Celldex Therapeutics by 12.2% in the third quarter. BlackRock Advisors LLC now owns 52,107 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 5,683 shares during the last quarter. Institutional investors and hedge funds own 78.41% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).

5 Day Chart for NASDAQ:CLDX

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.